Allosource Awarded Patent for New Cartilage Repair Product

Allosource has been awarded a U.S. patent for its new cartilage repair allograft, ProChondrix Cartilage Restoration Matrix.

ProChondrix is a cellular 3-D fresh cartilage matrix that helps deliver the necessary components for cartilage restoration, according to the company. This next-generation of cartilage therapy provides live functional cells and other biological components necessary for the repair and regeneration of damaged cartilage tissues.

“With thousands of cartilage repair surgeries performed in the U.S. each year, this is anothe opportunity for donor tissue to improve lives,” said Dr. Peter Stevens, Ph.D., Allosource’s vice president of Development and Growth. “The initial feedback from surgeons on ProChondrix has been positive and we look forward to continued collaboration in helping patients heal.”

The announcement of Patent Number 9,186,253 comes just three weeks after the securing of two other patents in late December. That first patent, titled “perforated osteochondral allograft compositions,” covers donated osteochondral tissue with a bone and cartilage layer perforated with small holes to allow for cellular migration and osteochondral repair. The second, titled, “minced cartilage systems and methods,” covers donated cartilage tissue processed to include small particles of cartilage containing living chondrocytes.

Allosource is one of the nation’s largest non-profit cellular and tissue networks, offering more than 200,000 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. The company’s products offer life-saving and life-enhancing alternatives in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, Colo.